TL;DR: The Centers for Medicare & Medicaid Services modified NCD 102, the National Coverage Determination governing Medicare lipid testing coverage, with an effective date of March 7, 2026. Here's what billing teams need to do.
CMS lipid testing coverage policy under NCD 102 has been updated. This policy governs Medicare reimbursement for total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride testing across a wide range of cardiovascular and metabolic indications. The policy does not list specific CPT or HCPCS codes, so your billing team will need to cross-reference your current charge capture against local coverage determinations from your Medicare Administrative Contractor. If you're not sure how NCD 102 Medicare requirements map to your payer mix, loop in your compliance officer before March 7, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Lipid Testing — NCD 102 |
| Policy Code | NCD 102 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | Medium — broad clinical scope, high claim volume |
| Specialties Affected | Cardiology, endocrinology, primary care, nephrology, internal medicine |
| Key Action | Audit your lipid panel claim frequency and documentation before March 7, 2026 |
CMS Lipid Testing Coverage Criteria and Medical Necessity Requirements 2026
The CMS lipid testing coverage policy under NCD 102 is built on one core principle: medical necessity tied to a recognized clinical indication. This isn't a blanket approval for routine cholesterol testing. CMS requires that your documentation connect the test to a specific condition or monitoring purpose.
The policy recognizes lipid testing as appropriate for evaluating atherosclerotic cardiovascular disease. That's the anchor. From there, it extends to a defined list of covered indications — but the diagnosis on the claim has to match.
Medical necessity for lipid testing is met when the patient has one of the following: atherosclerotic cardiovascular disease, primary dyslipidemia, any disease that leads to atherosclerotic formation, or a condition associated with altered lipid metabolism. That last category includes nephrotic syndrome, pancreatitis, hepatic disease, hypothyroidism, and hyperthyroidism. Secondary dyslipidemia — including diabetes mellitus, disorders of gastrointestinal absorption, and chronic renal failure — also qualifies.
Coronary heart disease (CHD) risk screening is another covered pathway. When total cholesterol exceeds 240 mg/dL, lipid testing qualifies as follow-up to the initial CHD screen. It also qualifies when total cholesterol is borderline-high (200–240 mg/dL) plus two or more CHD risk factors. And it qualifies when HDL cholesterol is below 35 mg/dL.
The policy doesn't require prior authorization for lipid testing directly. But your MAC may impose prior authorization or documentation requirements at the local level. Check your MAC's local coverage determination before assuming NCD 102 alone clears the claim.
Reimbursement for lipid testing depends on the specific fractions ordered and their medical necessity documentation. Total cholesterol, HDL-C, and LDL-C are the workhorses for monitoring anti-lipid therapy. Triglycerides come into play when that fraction is elevated or when the patient is on drugs known to raise triglyceride levels — thiazide diuretics, beta blockers, estrogens, glucocorticoids, and tamoxifen.
CMS Lipid Testing Frequency Limits and Medical Necessity Documentation
Frequency is where most lipid testing billing guidelines run into trouble. NCD 102 is specific here, and CMS auditors know these thresholds.
For patients on long-term anti-lipid dietary or pharmacologic therapy, an annual lipid panel is generally reasonable. Between those annual panels, total cholesterol or a measured LDL alone is usually enough — unless the patient has hypertriglyceridemia.
The first year of dietary or pharmacologic therapy is the exception. CMS allows any one component of the lipid panel, or a measured LDL, up to six times during that first year. That's for monitoring purposes only. Document why each test was ordered. "Monitoring therapy response" is not enough — your notes need to show what the result was, how it changed management, and why the frequency was appropriate.
More frequent testing than those thresholds requires clear clinical justification. If you're billing more than six lipid tests in year one, or more than annual panels after that, expect scrutiny. A claim denial is likely without solid documentation in the medical record.
Skin lesions as a sign or symptom of dyslipidemia are also a covered indication. That's a specific clinical detail worth noting — xanthomas and related skin findings support medical necessity documentation.
CMS Lipid Testing Exclusions and Non-Covered Indications
NCD 102 doesn't provide an explicit "excluded" list in the same way some policies do. But the structure of the policy makes the non-covered territory clear: testing without a qualifying indication is not covered.
Routine screening lipid testing for asymptomatic patients — with no cardiovascular disease, no dyslipidemia diagnosis, and no CHD risk factors that meet the threshold criteria — is not covered under NCD 102. The policy frames all covered testing around either a diagnosis or a defined risk threshold. If neither is present in the documentation, the claim won't hold up.
Testing frequency above the stated thresholds, without documented clinical justification, also falls outside coverage. This is the most common source of claim denial for lipid testing. Your billing team should know these frequency limits cold.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Atherosclerotic cardiovascular disease — assessment | Covered | Not specified in NCD 102 | Diagnosis must appear in documentation |
| Primary dyslipidemia — evaluation | Covered | Not specified in NCD 102 | Covers full panel as appropriate |
| Any atherosclerotic disease or disease leading to atherosclerosis | Covered | Not specified in NCD 102 | Broad category — document the specific condition |
| Altered lipid metabolism: nephrotic syndrome, pancreatitis, hepatic disease, hypo/hyperthyroidism | Covered | Not specified in NCD 102 | Specify the associated diagnosis on the claim |
| Secondary dyslipidemia: diabetes mellitus, GI absorption disorders, chronic renal failure | Covered | Not specified in NCD 102 | Comorbid diagnosis required in documentation |
| Signs or symptoms of dyslipidemias (e.g., skin lesions/xanthomas) | Covered | Not specified in NCD 102 | Clinical finding must be documented in the note |
| CHD screening follow-up: total cholesterol >240 mg/dL | Covered | Not specified in NCD 102 | Document the total cholesterol result |
| CHD screening follow-up: borderline-high cholesterol (200–240 mg/dL) + 2 or more risk factors | Covered | Not specified in NCD 102 | Document both the borderline result and the risk factors |
| CHD screening follow-up: HDL-C <35 mg/dL | Covered | Not specified in NCD 102 | Document the HDL result |
| Monitoring anti-lipid dietary or pharmacologic therapy — annual lipid panel | Covered | Not specified in NCD 102 | Annual frequency is the standard; document ongoing therapy |
| Monitoring therapy — up to 6 tests (any single component or measured LDL) in year one | Covered | Not specified in NCD 102 | Year one of new therapy only; document each clinical decision |
| Triglyceride testing when triglycerides are elevated | Covered | Not specified in NCD 102 | Document the elevated result or the clinical rationale |
| Triglyceride testing when patient is on thiazide diuretics, beta blockers, estrogens, glucocorticoids, or tamoxifen | Covered | Not specified in NCD 102 | Document the triggering medication in the record |
| Routine screening — no qualifying diagnosis or risk threshold | Not Covered | Not specified in NCD 102 | No clinical indication = no coverage |
| Testing above frequency thresholds without documented justification | Not Covered | Not specified in NCD 102 | Excess frequency is the top claim denial driver for this policy |
CMS Lipid Testing Billing Guidelines and Action Items 2026
| # | Action Item |
|---|---|
| 1 | Audit your lipid panel claim frequency now — before March 7, 2026. Pull all lipid testing claims from the past 12 months. Flag any patient with more than one full lipid panel unless they were in year one of therapy. Flag any patient with more than six tests in a 12-month period. Review those records for documentation. |
| 2 | Map your ICD-10 diagnosis codes to the covered indication list. NCD 102 doesn't list specific CPT or ICD-10 codes, but your claims need a qualifying diagnosis. Review your common diagnosis codes for lipid testing. Make sure every code on your charge capture maps to one of the covered indications — atherosclerotic disease, dyslipidemia, metabolic conditions, or a documented CHD risk threshold. |
| 3 | Document the clinical trigger for every triglyceride test. Triglycerides aren't automatically included with every lipid workup under this policy. If you're billing triglycerides, the record needs to show an elevated triglyceride level, or the patient's medication list needs to include one of the drugs flagged in the policy (thiazides, beta blockers, estrogens, glucocorticoids, tamoxifen). |
| 4 | Check your MAC's local coverage determination. NCD 102 sets the national floor. Your Medicare Administrative Contractor may have an LCD that adds documentation requirements, narrows the covered indication list, or specifies which CPT codes they expect. If you haven't read your MAC's lipid testing LCD recently, do it before the effective date of March 7, 2026. |
| 5 | Train your clinical documentation team on frequency rules. The six-tests-in-year-one limit is the most misunderstood part of this policy. Make sure your physicians know the threshold. More importantly, make sure they know what documentation is required when they cross it. A note that says "ordered lipid panel" won't survive an audit — the note needs to show why that test was needed at that frequency. |
| 6 | Review orders for patients on high-risk medications. Patients on thiazide diuretics, beta blockers, estrogens, glucocorticoids, or tamoxifen are candidates for triglyceride monitoring under this policy. Make sure your care teams flag these patients and document the clinical rationale at the time of ordering. That documentation is what keeps the claim paid and survives any medical necessity review. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Lipid Testing Under NCD 102
A Note on Codes Under NCD 102
NCD 102 does not specify CPT, HCPCS, or ICD-10 codes in the policy document. This is a known limitation of some CMS national coverage determinations — the national policy sets coverage criteria, and the specific codes are governed at the MAC level through local coverage determinations and accompanying billing articles.
For lipid testing billing, your team should:
- Contact your Medicare Administrative Contractor directly for the current code list associated with their LCD for lipid testing
- Review the applicable LCD billing article, which will list the specific CPT codes (commonly in the 80000 series for laboratory panels) that your MAC accepts under this coverage framework
- Cross-reference those codes against the indication-level criteria in NCD 102
Do not assume that any lipid-related CPT code is automatically covered under NCD 102 without confirming your MAC's specific requirements. Billing without that confirmation is the fastest path to a claim denial.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.